UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Other Current Assets

Last Annual Value

494.00K

3-Year CAGR

28%

5-Year CAGR

16%

10-Year CAGR

8%

UB

Upstream Bio, Inc. Competitors Analysis of Other Current Assets

UPB · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
494.00K
10.1%N/AN/A 
5.04M
115.5%6.0%61.8%
11.58M
47.9%N/AN/A
3.61M
17.0%N/AN/A
23.76M
92.8%68.2%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
9.52M
369.5%N/AN/A
7.98M
39.4%N/AN/A
7.25M
317.0%N/AN/A
0.00
N/AN/AN/A
15.35M
5.2%36.3%N/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97